Abstract

ACP Journal Club21 April 2009Review: Interferon and nucleoside/tide analogues reduce risk for hepatocellular cancer in patients with chronic hepatitis BAverell H. Sherker, MD, FRCP(C)Averell H. Sherker, MD, FRCP(C)Washington Hospital Center and Georgetown University, Washington, DC, USA (A.H.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-150-8-200904210-02011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationSung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067-77. https://pubmed.ncbi.nlm.nih.gov/18657133Clinical Impact RatingsGastroenterology: Infectious Disease: References1 Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315-41. [PMID: 18845489] Google Scholar2 Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36. [PMID: 16250051] Google Scholar Author, Article, and Disclosure InformationAuthors: Averell H. Sherker, MD, FRCP(C)Affiliations: Washington Hospital Center and Georgetown University, Washington, DC, USA (A.H.S.)This article was published at Annals.org on 7 April 2009. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 April 2009Volume 150, Issue 8Page: JC4-11KeywordsCancer preventionCancer treatmentChronic hepatitis BCirrhosisCohort studiesInfectious diseasesInfectious hepatitisInterferonsLiver transplantationTreatment guidelines ePublished: 21 April 2009 Issue Published: 21 April 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call